Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Some cardiovascular problems with disopyramide

S J Warrington, J Hamer

    Postgraduate Medical Journal
    |April 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Disopyramide can cause serious cardiovascular adverse effects, including arrhythmias and conduction abnormalities. Careful administration and patient selection are crucial to avoid potential harm from this antiarrhythmic drug.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Greater need but reduced access: a population study of planned and elective surgery rates in adult mental health service users.

    Epidemiology and psychiatric sciences·2024
    Same author

    Formal evaluation of PYNK: Breast Cancer Program for Young Women-the patient perspective.

    Current oncology (Toronto, Ont.)·2016
    Same author

    A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.

    European journal of clinical pharmacology·2013
    Same author

    Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    A comparison of 0.2 and 0.5 mg intrathecal morphine for postoperative analgesia after total knee replacement.

    Anaesthesia·2005
    Same author

    Acute posttraumatic paraplegia associated with asymptomatic thoracic meningioma.

    Acta neurochirurgica·2005
    Same journal

    Dapagliflozin-induced anaphylactic shock.

    Postgraduate medical journal·2026
    Same journal

    Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials.

    Postgraduate medical journal·2026
    Same journal

    Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

    Postgraduate medical journal·2026
    Same journal

    Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

    Postgraduate medical journal·2026
    Same journal

    Care, cash, and proof: forensic accountability for war-related starvation.

    Postgraduate medical journal·2026
    Same journal

    Response to traumatic injuries in polo players in England.

    Postgraduate medical journal·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Clinical Pharmacology

    Background:

    • Disopyramide is an antiarrhythmic medication used to treat certain heart rhythm disorders.
    • Understanding its cardiovascular adverse effects is critical for safe clinical practice.

    Observation:

    • Review of five patients revealed significant cardiovascular adverse events associated with disopyramide use.
    • Observed effects include sinus tachycardia with aberrant conduction, bradycardia, and asystolic cardiac arrest.

    Findings:

    • Disopyramide's vagolytic effects can mimic or exacerbate arrhythmias.
    • It may provoke ventricular arrhythmias in susceptible individuals, similar to quinidine.
    • Rapid intravenous administration can lead to transient toxic effects.

    Implications:

    Related Experiment Videos

    • Disopyramide should be used with caution, especially in patients with pre-existing conduction system disease.
    • Consideration for demand pacemaker use is advised in certain patients.
    • Slower intravenous injection rates are recommended for prophylaxis to mitigate risks.